Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia—an update on behalf of the ALWP of the EBMT

Bone Marrow Transplantation volume 54, pages 713–718 (2019)Cite this article

Abstract

Allogeneic stem cell transplantations (alloSCT) from haploidentical (>2 HLA mismatch) donors (HaploSCT) are constantly increasing in Europe. From 2005 to 2015 numbers of HaploSCT increased by close to 300%. In parallel, there is a major shift from T deplete (CD34+ megadose) to T replete (non-T deplete) HaploSCT. Graft versus host disease (GVHD) prophylaxis also changed from CD34+ cell purifications to anti-thymocyte globulin (ATG) and lately to post-transplantation cyclophosphamide (PTCy). Novel conditioning regimens have been developed incorporating novel drugs and innovative approaches. Results are persistently improving and currently, registry-based and single-center studies showed no statistical significance difference in transplantation outcome between HaploSCT to alloSCT from unrelated donors and even from HLA-matched sibling donors, although the numbers of those studies are small and the lack of randomized studies available so far. HaploSCT have several advantages and such as the possibility to choose between different potential donors. Parameters to consider in the Haplo donor selection are age, gender, kinship, ABO blood group, CMV status, non-shared HLA Haplotypes and killer cell immunoglobulin-like receptor (KIR). Future goals are to further decrease transplant-related mortality currently mainly due to infection complications and reduce relapse rates especially in patients with high-risk acute leukemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112:3574–81. https://doi.org/10.1182/blood-2008-02-140095.

    Article  CAS  PubMed  Google Scholar 

  2. Kapelushnik J, Mandel H, Varadi G, Nagler A. Fludarabine-based protocol for haploidentical peripheral blood stem cell transplantation in Hurler syndrome. J Pedia Hematol Oncol. 2000;22:433–6.

    Article  CAS  Google Scholar 

  3. Varadi G, Svirsky O, Nagler A. Successful major surgical recovery of a patient following haploidentical stem cell transplantation for chronic myeloid leukemia in blast crisis and aspergillosis. Acta Haematol. 2002;108:29–32.

    Article  Google Scholar 

  4. Piemontese S, Ciceri F, Labopin M, Bacigalupo A, Huang H, Santarone S, et al. A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1069–75. https://doi.org/10.1038/leu.2014.336.

    Article  CAS  PubMed  Google Scholar 

  5. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51:786–92. https://doi.org/10.1038/bmt.2016.20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52:811–7. https://doi.org/10.1038/bmt.2017.34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018. https://doi.org/10.1038/s41409-018-0153-1.

  8. Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, et al. Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant. 2016;22:23–6. https://doi.org/10.1016/j.bbmt.2015.11.001.

    Article  PubMed  Google Scholar 

  9. Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, et al. Reprint of: haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant. 2016;22(3 Suppl):S15–8. https://doi.org/10.1016/j.bbmt.2016.01.006.

    Article  PubMed  Google Scholar 

  10. Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrcz-Krzemien S, Santarone S, et al. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017;10:24 https://doi.org/10.1186/s13045-017-0394-2.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sun Y, Beohou E, Labopin M, Volin L, Milpied N, Yakoub-Agha I, et al. Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. Haematologica. 2016;101:e352–4. https://doi.org/10.3324/haematol.2015.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11:55 https://doi.org/10.1186/s13045-018-0598-0.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ruggeri A, Ciceri F, Gluckman E, Labopin M, Rocha V. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors? Best Pr Res Clin Haematol. 2010;23:207–16. https://doi.org/10.1016/j.beha.2010.06.002.

    Article  Google Scholar 

  14. Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891–900. https://doi.org/10.1038/leu.2015.98.

    Article  CAS  PubMed  Google Scholar 

  15. Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017;1:477–85. https://doi.org/10.1182/bloodadvances.2016002386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018. pii: haematol 2018:189258. https://doi.org/10.3324/haematol.2018.189258.

    Article  CAS  Google Scholar 

  17. Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, et al. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018. https://doi.org/10.1002/ajh.25231.

  18. Canaani J, Labopin M, Huang XJ, Arcese W, Ciceri F, Blaise D, et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:736–44. https://doi.org/10.1002/ajh.25082.

    Article  CAS  PubMed  Google Scholar 

  19. Li Z, Labopin M, Ciceri F, Blaise D, Tischer J, Ehninger G, et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol. 2018;93:769–77. https://doi.org/10.1002/ajh.25087.

    Article  CAS  PubMed  Google Scholar 

  20. Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation. Exp Hematol. 2000;28:1225–31.

    Article  CAS  Google Scholar 

  21. Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63:204–11.

    Article  CAS  Google Scholar 

  22. Ringdén O, Labopin M, Ciceri F, Velardi A, Bacigalupo A, Arcese W, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia. 2016;30:447–55. https://doi.org/10.1038/leu.2015.232.

    Article  CAS  PubMed  Google Scholar 

  23. Canaani J, Labopin M, Huang HJ, Ciceri F, Van Lint MT, Bruno B, et al. Minimal residual disease status predicts outcome of acute myeloid leukemia patients undergoing T-Cell replete haploidentical transplantation. An analysis from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2018. https://doi.org/10.1111/bjh.15540.

  24. Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gülbaş Z, et al. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017;10:113. https://doi.org/10.1186/s13045-017-0480-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2013;121:849–57. https://doi.org/10.1182/blood-2012-08-453399.

    Article  CAS  PubMed  Google Scholar 

  26. Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, et al. Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget. 2017;9:3379–93. https://doi.org/10.18632/oncotarget.23273.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Rubio MT, Savani BN, Labopin M, Piemontese S, Polge E, Ciceri F, et al. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. J Hematol Oncol. 2016;9:25. https://doi.org/10.1186/s13045-016-0248-3.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, et al. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI-Based Regimen. Clin Cancer Res. 2018;24:2794–803. https://doi.org/10.1158/1078-0432.CCR-17-3622.

    Article  CAS  PubMed  Google Scholar 

  29. Ruggeri A, Labopin M, Bacigalupo A, Gülbas Z, Koc Y, Blaise D, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018;124:1428–37. https://doi.org/10.1002/cncr.31228.

    Article  CAS  PubMed  Google Scholar 

  30. Ruggeri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017;102:401–10. https://doi.org/10.3324/haematol.2016.151779.

    Article  Google Scholar 

  31. Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224–34. https://doi.org/10.3324/haematol.2016.148510.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018;11:40 https://doi.org/10.1186/s13045-018-0586-4.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Gorin NC, Labopin M, Piemontese S, Arcese W, Santarone S, Huang H, et al. T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. Haematologica. 2015;100:558–64. https://doi.org/10.3324/haematol.2014.111450.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Lorentino F, Labopin M, Fleischhauer K, Ciceri F, Mueller CR, Ruggeri A, et al. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv. 2017;1:669–80. https://doi.org/10.1182/bloodadvances.2017006429.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, et al. Related donor transplants: has post transplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018;2:1180–6. https://doi.org/10.1182/bloodadvances.2018018291.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018;93:246–53. https://doi.org/10.1002/ajh.24963.

    Article  PubMed  Google Scholar 

  37. Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017;102:1066–74. https://doi.org/10.3324/haematol.2016.160804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Cesaro S, Crocchiolo R, Tridello G, Knelange N, Van Lint MT, Koc Y, et al. Comparable survival using a CMV-matched or a mismatched donor for CMV+patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplant. 2018;53:422–30. https://doi.org/10.1038/s41409-017-0016-1.

    Article  CAS  Google Scholar 

  39. Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, Gülbas Z, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2018. https://doi.org/10.1038/s41375-018-0170-5.

  40. Sestili S, Labopin M, Ruggeri A, Velardi A, Ciceri F, Maertens J, et al. T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). Cancer. 2018;124:2142–50. https://doi.org/10.1002/cncr.31310.

    Article  CAS  PubMed  Google Scholar 

  41. Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, et al. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:1810–22. https://doi.org/10.3324/haematol.2017.176107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Publication of this supplement was sponsored by Gilead Sciences Europe Ltd, Cell Source, Inc., The Chorafas Institute for Scientific Exchange of the Weizmann Institute of Science, Kiadis Pharma, Miltenyi Biotec, Celgene, Centro Servizi Congressuali, Almog Diagnostic.

Author information

Authors and Affiliations

  1. Chaim Sheba Medical Center, Tel Hashomer, Israel

    Arnon Nagler

  2. Department of Pediatric Hematology and Oncology IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy

    Annalisa Ruggeri

Authors
  1. Arnon Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annalisa Ruggeri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnon Nagler.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest to disclose

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagler, A., Ruggeri, A. Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia—an update on behalf of the ALWP of the EBMT. Bone Marrow Transplant 54 (Suppl 2), 713–718 (2019). https://doi.org/10.1038/s41409-019-0610-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0610-5

This article is cited by

Search

Advanced search

Quick links